Browsing Tag
Rhythm Pharmaceuticals Inc.
1 post
Superluminal lands $60m Series B to take genetic obesity drug into human trials
Superluminal Medicines has secured an oversubscribed $60 million Series B to move a selective small-molecule MC4R agonist into Phase 1, entering an obesity niche where Rhythm Pharmaceuticals already generates more than $70 million a quarter.